Obiettivo
Colorectal cancer is the third most common cancer in the world, with nearly 1.4 million new cases diagnosed in 2012. The frequency of complications after surgery is relatively high, but rapid and safe monitoring methods are missing.
MD Biomedical AB has addressed this need and developed a radically new and innovative piece of medical equipment that is gently attached on the surface of the bowel for sampling of biomakers. This makes it possible to detect complications within minutes, at an early stage of illness, and long before patient systemic indications.
The possibility of rapid counteractions improves the treatment of the patient and save health care costs.
The feasibility study comprises one work package divided in 6 tasks and shall in measurable terms assess the functional, medical, economic, and environmental effects and the deliverable is a feasibility report including a business plan.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEINST-1-2014
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
90719 UMEA
Svezia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.